Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arterial Inflammation Clear all
Completed Not applicable Interventional Results available

Statin Therapy to Improve Atherosclerosis in HIV Patients

NCT00965185
View directory record Official record
Conditions
Cardiovascular Disease, HIV, Atherosclerosis, Inflammation, Statins, HMG-CoA, HIV Infections
Interventions
atorvastatin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

NCT04930094
View directory record Official record
Conditions
Giant Cell Arteritis (GCA)
Interventions
Secukinumab 300 mg, Placebo, Secukinumab 150 mg
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Plantation, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Not applicable Interventional Results available

Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention

NCT00588471
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Baricitinib in Relapsing Giant Cell Arteritis

NCT03026504
View directory record Official record
Conditions
Arteritis, Giant Cell
Interventions
Baricitinib
Drug
Lead sponsor
Matthew J Koster
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

NCT00547976
View directory record Official record
Conditions
Atherosclerosis, Healthy
Interventions
[C-11]PBR28
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Jul 24, 2026, 1:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

NCT02257866
View directory record Official record
Conditions
Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis, ANCA-Associated Vasculitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
3 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

NCT01791153
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Tocilizumab, Prednisone, Tocilizumab Placebo, Prednisone Placebo, Corticosteroids, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Los Angeles, California • Boca Raton, Florida • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Jul 24, 2026, 1:53 AM EDT
Recruiting No phase listed Observational

VCRC Tissue Repository

NCT02967068
View directory record Official record
Conditions
Aortitis, Cutaneous Vasculitis, Eosinophilic Granulomatosis With Polyangiitis, Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Henoch-Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Churg-Strauss Syndrome
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
6
States / cities
Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Completed No phase listed Observational Results available

PET/CT Imaging Companion Study To ACTG A5314

NCT02312219
View directory record Official record
Conditions
HIV, Inflammation, Atherosclerosis
Interventions
Folic Acid, Placebo, Low Dose Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

NCT02531633
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Not applicable Interventional Results available

The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan

NCT01238588
View directory record Official record
Conditions
Dialysis, Cardiovascular Disease, Atherosclerosis, Inflammation, Hyperphosphatemia
Interventions
Sevelamer Carbonate (Renvela)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Boston, Massachusetts • Framingham, Massachusetts • Marlborough, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

NCT00552188
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
VIA-2291, Placebo
Drug
Lead sponsor
Tallikut Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis

NCT04271735
View directory record Official record
Conditions
Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia, Cardiometabolic Diseases
Interventions
Niagen, Placebo
Dietary Supplement · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lipoic Acid and Prevention of Heart Disease

NCT00765310
View directory record Official record
Conditions
Atherosclerosis
Interventions
R-alpha lipoic acid, Placebo
Dietary Supplement
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

NCT02998918
View directory record Official record
Conditions
Inflammation, Atherosclerosis, Cardiovascular Disease
Interventions
PolyResveratrol Supplementation, Curcumin Supplementation
Dietary Supplement
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 24, 2026, 1:53 AM EDT
Completed No phase listed Observational

Non-Invasive Imaging of Atherosclerosis

NCT01418313
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
20 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

NCT05630885
View directory record Official record
Conditions
HIV-1-infection, Elevated Cardiovascular Risk
Interventions
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
45 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

NCT02729025
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Miami, Florida • Las Vegas, Nevada • Mooresville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Jul 24, 2026, 1:53 AM EDT
Withdrawn No phase listed Observational

Carotid Plaque Regression With Statin Treatment Assessed by High Field Magnetic Resonance Imaging (MRI)

NCT00388843
View directory record Official record
Conditions
Carotid Atherosclerosis
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

NCT00330733
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Inflammation, Insulin Resistance, Noninsulin-dependent Diabetes Mellitus
Interventions
Salsalate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Early Phase 1 Interventional

Angiotensin-(1-7) in Peripheral Arterial Disease

NCT03240068
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Angiotensin 1-7, Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 24, 2026, 1:53 AM EDT
Recruiting No phase listed Observational

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

NCT03004326
View directory record Official record
Conditions
Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis
Interventions
Not listed
Lead sponsor
Peter Merkel
Other
Eligibility
5 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jul 24, 2026, 1:53 AM EDT